| Stephanie F Kohlhepp, PT | |
|
1262 W Clairemont Ave, Eau Claire, WI 54701-6125 | |
| (715) 858-4610 | |
| Not Available |
| Full Name | Stephanie F Kohlhepp |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 1262 W Clairemont Ave, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154416428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 5187 (Wisconsin) | Primary |
| Provider Name | Marshfield Clinic Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Not even the most avid fans could notice, but those spectacular aerial images of a brightly-lit Cowboys Stadium during Sunday's Super Bowl XLV symbolize one of the hottest new pieces of scientific intelligence about air pollution.
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
› Verified 1 days ago
| Provider Name | Mchs Hospitals Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Not even the most avid fans could notice, but those spectacular aerial images of a brightly-lit Cowboys Stadium during Sunday's Super Bowl XLV symbolize one of the hottest new pieces of scientific intelligence about air pollution.
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
› Verified 1 days ago
| Provider Name | Lakeview Medical Center Inc Of Rice Lake |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093201832 PECOS PAC ID: 6103737820 Enrollment ID: O20180817001484 |
News Archive
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Not even the most avid fans could notice, but those spectacular aerial images of a brightly-lit Cowboys Stadium during Sunday's Super Bowl XLV symbolize one of the hottest new pieces of scientific intelligence about air pollution.
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie F Kohlhepp, PT 1000 N Oak Ave, Marshfield, WI 54449-5703 Ph: (715) 387-5511 | Stephanie F Kohlhepp, PT 1262 W Clairemont Ave, Eau Claire, WI 54701-6125 Ph: (715) 858-4610 |
News Archive
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.
ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Not even the most avid fans could notice, but those spectacular aerial images of a brightly-lit Cowboys Stadium during Sunday's Super Bowl XLV symbolize one of the hottest new pieces of scientific intelligence about air pollution.
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
› Verified 1 days ago
Anna Marie Byrne, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2116 Craig Rd, Eau Claire, WI 54701 Phone: 715-858-4500 | |
Andrew J Strope, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 517 E Clairemont Ave, Eau Claire, WI 54701 Phone: 715-855-0408 | |
Kasey Kruse, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Lori M Stress, MPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1262 W Clairemont Ave, Eau Claire, WI 54701 Phone: 715-858-4610 | |
Mrs. Holli Ann Kloss, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Mr. Paul F Greene, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Jessica Marie Ortiz-peterson, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 |